Home » Study Reveals 63% of Pharmaceutical Companies Rely on Third-Party Outsourcing
Study Reveals 63% of Pharmaceutical Companies Rely on Third-Party Outsourcing
PharmaManufacturing.com
08/10/2010
IDC Health Insights recently announced the availability of a new report, Vendor Assessment: Life Science Buyers Guide to Manufacturing and Supply Chain IT Outsourcing (Doc #HI223980, July 2010) that reveals that life science companies are increasingly utilizing third-party outsourcing firms to both augment and/or replace varying aspects of their IT responsibilities, with continued growth in spending on these services expected over the next 12 months.
"With the global recession now in the rear view mirror, life science companies are slowly shifting their primary cost-cutting focus back toward long-term top-line growth," said Eric Newmark, research manager with IDC Health Insights. "Manufacturing and supply chain strategies not only remain a critical component of maintaining lower-costs, but also hold the key to reducing corporate liability, protecting brand equity and optimizing operational efficiency."
Key findings of the study include the following:
In a 2008 IDC Health Insights study, 48% of pharmaceutical companies suggested they outsourced some aspect of manufacturing or supply chain related IT. Over the past two years, this number has risen to 63%, demonstrating the growing importance of outsourcing within manufacturing and supply chain operations.
Industry sentiment and adoption trends all point to continued growth in IT outsourcing between 4-6% over the next 12-18 months, followed by moderate growth of approximately 4% annually for the next 2 to 3 years.
Of the 63% of companies currently outsourcing some aspect of manufacturing or supply chain operations, approximately 18% use only U.S.-based firms, 4% use only offshore firms, and 41% use a mix of both.
Technologies that support increased supply chain visibility and monitoring capabilities, as well as analytics and business intelligence solutions, are expected to be front and center this year.
This report provides a decision framework and a wide array of vendor-evaluative details on the top 12 vendors that provide IT outsourcing services for life science manufacturing and supply chain operations. The vendors include: Capgemini, Cognizant, CSC, HCL, IBM, Infosys, Intelligroup, Satyam, Wipro, Persistent, TAKE Solutions, and Tata Consultancy Services (TCS). The vendors are compared and contrasted across four major components (industry expertise, delivery expertise, customer references and industry focus) and 22 application-specific/functional areas of experience. Information included in this report is meant to serve as a starting point from which companies can launch their decision processes.
More News:
-
02/09/2012
Watchdog Fines Ernst & Young $2 million Over Medicis Pharma Corp. AuditsFrom Reuters.com
The watchdog board for corporate auditors on Wednesday said it has imposed a $2 million penalty, its largest fine ever, on accounting and consulting firm Ernst & Young LLP in a settlement involving past audits of Medicis Pharmaceutical Corp.
-
02/09/2012
FDA Issues Draft Guidance on Biosimilar Product Development
The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.
-
02/08/2012
Biomedical Industry Loses Momentum in California, According to 2012 Report
Innovation slows as productivity in the Biomedical industry declines
-
02/02/2012
Pfizer Baby Boom? Pfizer's Official StatementFrom Pharmalot.com
About nine months from now, a new phenomenon may appear at a hospital near you: the Pfizer baby. Why? The drugmaker has taken the embarrassing step of recalling 1 million packets of birth control pills due to a packaging error. Hear EVP and CMO, Freda Lewis-Hall's read Pfizer's official statement.
-
02/02/2012
News: AstraZeneca To Cut 7,300 JobsFrom MarketWatch.com
Drug firm AstraZeneca on Thursday said it would cut approximately 7,300 jobs as part of an ongoing initiative to reduce costs and drive innovation.
-
02/01/2012
Pfizer Recalls 1 Million Birth Control Packs for Error That Could Cause Unintended PregnancyFrom WashingtonPost.com
Pfizer Inc. is recalling 1 million packets of birth control pills due to a packaging error that could raise the risk of an accidental pregnancy by leaving women with an inadequate dose. The problem affects 14 lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in the U.S. by Akrimax Rx Products under the Akrimax Pharmaceuticals brand.
-
01/26/2012
News: Abbott Labs Cuts 700 Manufacturing JobsFrom WashingtonPost.com
Medical device and drugmaker Abbott Laboratories said Wednesday it will lay off 700 employees as part of ongoing restructuring efforts. A company spokeswoman said most of the layoffs will affect employees who manufacture the company’s heart stents and diagnostic tests.
- 01/24/2012 ISPE Announces 2012 FOYA Winners
- 01/24/2012 Genzyme Gains Approval for Framingham Site, a Boost to Fabrazyme Production
-
01/19/2012
Big Pharma Execs May Wish They'd Never Heard Of Paula DeenFrom Forbes.com
Novo Nordisk has nabbed Paula Deen as a new spokeswoman to help raise awareness about type 2 diabetes. Many in the drug industry wish it weren’t so, but without major legal and regulatory changes, such matches between celebs and drug firms are as certain as the sun rising in the east.
- All news »
Get Connected Now!
- Featured White Papers

Print page